Supportive care, growth factors, and new therapies in myelodysplastic syndromes

Cazzola, 2005, Myelodysplastic syndromes–coping with ineffective hematopoiesis, N Engl J Med, 352, 536, 10.1056/NEJMp048266 Bennett, 1982, Proposals for the classification of the myelodysplastic syndromes, Br J Haematol, 51, 189, 10.1111/j.1365-2141.1982.tb08475.x Vardiman, 2002, The World Health Organization (WHO) classification of the myeloid neoplasms, Blood, 100, 2292, 10.1182/blood-2002-04-1199 Germing, 2000, Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients, Leuk Res, 24, 983, 10.1016/S0145-2126(00)00088-6 Malcovati, 2005, Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria. A basis for clinical decision-making, J Clin Oncol, 23, 7594, 10.1200/JCO.2005.01.7038 Howe, 2004, The WHO classification of MDS does make a difference, Blood, 103, 3265, 10.1182/blood-2003-06-2124 Verburgh, 2003, Additional prognostic value of bone marrow histology in patients subclassified according to the International Prognostic Scoring System for myelodysplastic syndromes, J Clin Oncol, 21, 273, 10.1200/JCO.2003.04.182 Greenberg, 1997, International scoring system for evaluating prognosis in myelodysplastic syndromes, Blood, 89, 2079, 10.1182/blood.V89.6.2079 de Witte, 2001, Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS, Blood, 98, 2326, 10.1182/blood.V98.8.2326 Malcovati, 2005, A WHO Classification-Based Prognostic Scoring System (WPSS) for Predicting Survival in Myelodysplastic Syndromes, Blood, 106, 788, 10.1182/blood.V106.11.788.788 Bowen, 2002, Treatment of Anemia in Myelodysplastic Syndromes, 345 Maschek, 1993, Hypoplastic myelodysplastic syndrome: incidence, morphology, cytogenetics, and prognosis, Ann Hematol, 66, 117, 10.1007/BF01697619 Vander Heiden, 1999, Bcl-2 proteins: regulators of apoptosis or of mitochondrial homeostasis?, Nat Cell Biol, 1, E209, 10.1038/70237 Wajant, 2002, The Fas signaling pathway: more than a paradigm, Science, 296, 1635, 10.1126/science.1071553 De Maria, 1999, Apoptotic role of Fas/Fas ligand system in the regulation of erythropoiesis, Blood, 93, 796, 10.1182/blood.V93.3.796 Claessens, 2002, In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis, Blood, 99, 1594, 10.1182/blood.V99.5.1594 Claessens, 2005, Rescue of early-stage myelodysplastic syndrome-deriving erythroid precursors by the ectopic expression of a dominant-negative form of FADD, Blood, 105, 4035, 10.1182/blood-2004-08-3166 Tehranchi, 2003, Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors, Blood, 101, 1080, 10.1182/blood-2002-06-1774 Tehranchi, 2005, Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes, Blood, 106, 247, 10.1182/blood-2004-12-4649 Bouscary, 1997, Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes, Leukemia, 11, 839, 10.1038/sj.leu.2400654 Verhoef, 1992, Measurement of serum cytokine levels in patients with myelodysplastic syndromes, Leukemia, 6, 1268 Otsuki, 1999, Tumor necrosis factor-alpha and CD95 ligation suppress erythropoiesis in Fanconi anemia C gene knockout mice, J Cell Physiol, 179, 79, 10.1002/(SICI)1097-4652(199904)179:1<79::AID-JCP10>3.0.CO;2-O Hellstrom-Lindberg, 2001, Apoptosis in refractory anaemia with ringed sideroblasts is initiated at the stem cell level and associated with increased activation of caspases, Br J Haematol, 112, 714, 10.1046/j.1365-2141.2001.02581.x May, 1982, Erythroblast iron metabolism in sideroblastic marrows, Br J Haematol, 52, 611, 10.1111/j.1365-2141.1982.tb03937.x Sakura, 1998, Ultrastructural abnormalities of bone marrow erythroblasts in refractory anemia, Ultrastruct Pathol, 22, 173, 10.3109/01913129809033469 van de Loosdrecht, 2001, Mitochondrial disruption and limited apoptosis of erythroblasts are associated with high risk myelodysplasia. An ultrastructural analysis, Leuk Res, 25, 385, 10.1016/S0145-2126(00)00151-X Gattermann, 2004, Ineffective hematopoiesis linked with a mitochondrial tRNA mutation (G3242A) in a patient with myelodysplastic syndrome, Blood, 103, 1499, 10.1182/blood-2003-07-2446 Shin, 2003, Mitochondrial DNA mutations in patients with myelodysplastic syndromes, Blood, 101, 3118, 10.1182/blood-2002-06-1825 Cazzola, 2003, Mitochondrial ferritin expression in erythroid cells from patients with sideroblastic anemia, Blood, 101, 1996, 10.1182/blood-2002-07-2006 Della Porta, 2005, Mitochondrial Ferritin Expression and Clonality of Hematopoiesis in Patients with Refractory Anemia with Ringed Sideroblasts, Blood, 106, 3444, 10.1182/blood.V106.11.3444.3444 Parker, 2004, The myelodysplastic syndromes: a matter of life or death, Acta Haematol, 111, 78, 10.1159/000074488 Barrett, 2000, Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology?, Semin Hematol, 37, 15, 10.1016/S0037-1963(00)90027-1 Saunthararajah, 2002, HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome, Blood, 100, 1570, 10.1182/blood.V100.5.1570.h81702001570_1570_1574 Molldrem, 1997, Antithymocyte globulin for patients with myelodysplastic syndrome, Br J Haematol, 99, 699, 10.1046/j.1365-2141.1997.4423249.x Aguayo, 2004, The role of angiogenesis in the biology and therapy of myelodysplastic syndromes, Curr Hematol Rep, 3, 184 Panoskaltsis, 2005, Dendritic cells in MDS and AML–cause, effect or solution to the immune pathogenesis of disease?, Leukemia, 19, 354, 10.1038/sj.leu.2403634 Delforge, 2005, CD34+ marrow progenitors from MDS patients with high levels of intramedullary apoptosis have reduced expression of alpha4beta1 and alpha5beta1 integrins, Leukemia, 19, 57, 10.1038/sj.leu.2403551 Kiladjian, 2006, Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes, Leukemia, 20, 463, 10.1038/sj.leu.2404080 Lai, 1995, Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoiesis and a high incidence of P53 mutations, Leukemia, 9, 370 Christiansen, 2001, Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis, J Clin Oncol, 19, 1405, 10.1200/JCO.2001.19.5.1405 Parker, 1998, ‘Low-risk’ myelodysplastic syndrome is associated with excessive apoptosis and an increased ratio of pro- versus anti-apoptotic bcl-2-related proteins, Br J Haematol, 103, 1075, 10.1046/j.1365-2141.1998.01114.x Parker, 2000, The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS, Blood, 96, 3932, 10.1182/blood.V96.12.3932 Rajapaksa, 1996, Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells, Blood, 88, 4275, 10.1182/blood.V88.11.4275.4275 Reuter, 2000, Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?, Blood, 96, 1655, 10.1182/blood.V96.5.1655 Shih, 2004, Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia, Leukemia, 18, 466, 10.1038/sj.leu.2403274 Gallagher, 1997, RAS and the myelodysplastic syndromes, Pathol Biol (Paris), 45, 561 List, 2004, Myelodysplastic syndromes, Hematology (Am Soc Hematol Educ Program), 297, 10.1182/asheducation-2004.1.297 Kamb, 1994, A cell cycle regulator potentially involved in genesis of many tumor types, Science, 264, 436, 10.1126/science.8153634 Hirama, 1995, Role of the cyclin-dependent kinase inhibitors in the development of cancer, Blood, 86, 841, 10.1182/blood.V86.3.841.841 Uchida, 1997, Hypermethylation of the p15INK4B gene in myelodysplastic syndromes, Blood, 90, 1403, 10.1182/blood.V90.4.1403 Quesnel, 1998, Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression, Blood, 91, 2985, 10.1182/blood.V91.8.2985.2985_2985_2990 Daskalakis, 2002, Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2’-deoxycytidine (decitabine) treatment, Blood, 100, 2957, 10.1182/blood.V100.8.2957 Batova, 2002, The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines, Blood, 100, 3319, 10.1182/blood-2002-02-0567 Kuendgen, 2004, Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid, Blood, 104, 1266, 10.1182/blood-2003-12-4333 Izaks, 1999, The definition of anemia in older persons, Jama, 281, 1714, 10.1001/jama.281.18.1714 Penninx, 2003, Anemia and decline in physical performance among older persons, Am J Med, 115, 104, 10.1016/S0002-9343(03)00263-8 Wu, 2001, Blood transfusion in elderly patients with acute myocardial infarction, N Engl J Med, 345, 1230, 10.1056/NEJMoa010615 Hellstrom-Lindberg, 2003, A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin+granulocyte colony-stimulating factor: significant effects on quality of life, Br J Haematol, 120, 1037, 10.1046/j.1365-2141.2003.04153.x Jansen, 2003, Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes, Br J Haematol, 121, 270, 10.1046/j.1365-2141.2003.04272.x Alessandrino, 2002, Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology, Haematologica, 87, 1286 Bowen, 2003, Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes, Br J Haematol, 120, 187, 10.1046/j.1365-2141.2003.03907.x Cutler, 2004, A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome, Blood, 104, 579, 10.1182/blood-2004-01-0338 Angelucci, 2002, Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation, Blood, 100, 17, 10.1182/blood.V100.1.17 Franchini, 2000, Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload, Blood, 95, 2776, 10.1182/blood.V95.9.2776.009k26_2776_2779 Cappellini, 2006, A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia, Blood, 107, 3455, 10.1182/blood-2005-08-3430 Cantor, 2002, Transcriptional regulation of erythropoiesis: an affair involving multiple partners, Oncogene, 21, 3368, 10.1038/sj.onc.1205326 Testa, 2004, Apoptotic mechanisms in the control of erythropoiesis, Leukemia, 18, 1176, 10.1038/sj.leu.2403383 Aul, 1991, Serum erythropoietin concentrations in patients with myelodysplastic syndromes, Leuk Res, 15, 571, 10.1016/0145-2126(91)90025-O Hellstrom, 1991, Treatment of myelodysplastic syndromes with recombinant human erythropoietin, Eur J Haematol, 47, 355, 10.1111/j.1600-0609.1991.tb01860.x Bowen, 1991, The treatment of anaemia in the myelodysplastic syndromes with recombinant human erythropoietin, Br J Haematol, 77, 419, 10.1111/j.1365-2141.1991.tb08594.x Aloe Spiriti, 1993, Recombinant human erythropoietin in the treatment of myelodysplastic syndromes. An interim report, Haematologica, 78, 123 Hellstrom-Lindberg, 1995, Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies, Br J Haematol, 89, 67, 10.1111/j.1365-2141.1995.tb08909.x Stein, 1991, Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes, Blood, 78, 1658, 10.1182/blood.V78.7.1658.1658 A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes. Br J Haematol 1998;103:1070–1074. Hellstrom-Lindberg, 1997, Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model, Br J Haematol, 99, 344, 10.1046/j.1365-2141.1997.4013211.x Cheson, 2000, Report of an international working group to standardize response criteria for myelodysplastic syndromes, Blood, 96, 3671 Cheson, 2006, Clinical application and proposal for modification of the international working group (IWG) response criteria in myelodysplasia, Blood, 10.1182/blood-2005-10-4149 Terpos, 2002, Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients, Br J Haematol, 118, 174, 10.1046/j.1365-2141.2002.03583.x Verhoef, 1992, Cytogenetic effects on cells derived from patients with myelodysplastic syndromes during treatment with hemopoietic growth factors, Leukemia, 6, 766 Rigolin, 2004, In patients with myelodysplastic syndromes response to rHuEPO and G-CSF treatment is related to an increase of cytogenetically normal CD34 cells, Br J Haematol, 126, 501, 10.1111/j.1365-2141.2004.05086.x Ljung, 2004, Hypochromic red blood cells in low-risk myelodysplastic syndromes: effects of treatment with hemopoietic growth factors, Haematologica, 89, 1446 Bennett, 2004, Pure red-cell aplasia and epoetin therapy, N Engl J Med, 351, 1403, 10.1056/NEJMoa040528 Mannone, 2006, High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study, Br J Haematol, 133, 513, 10.1111/j.1365-2141.2006.06070.x Musto, 2005, Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes, Br J Haematol, 128, 204, 10.1111/j.1365-2141.2004.05288.x Stasi, 2005, Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes, Ann Oncol, 16, 1921, 10.1093/annonc/mdi400 Negrin, 1993, Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin, Blood, 82, 737, 10.1182/blood.V82.3.737.737 Negrin, 1996, Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy, Blood, 87, 4076, 10.1182/blood.V87.10.4076.bloodjournal87104076 Hellstrom-Lindberg, 1998, Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients, Blood, 92, 68, 10.1182/blood.V92.1.68.413k23_68_75 Remacha, 1999, Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group, Haematologica, 84, 1058 Casadevall, 2004, Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial, Blood, 104, 321, 10.1182/blood-2003-07-2252 Balleari, 2006, Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study, Ann Hematol, 85, 174, 10.1007/s00277-005-0044-6 Bowen, 2006, Predicting erythroid response to recombinant erythropoietin plus granulocyte colony-stimulating factor therapy following a single subcutaneous bolus in patients with myelodysplasia, Haematologica, 91, 709 Jadersten, 2005, Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF, Blood, 106, 803, 10.1182/blood-2004-10-3872 Jädersten, 2006, Treatment with Erythropoietin and G-CSF Improves Survival in MDS Patients with Low Transfusion Need, Blood, 106, 172 Park S, Grabar S, Kelaidi C, Beyne-Rauzy O, Picard F, Bardet V et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood Available online 16 October 2007. Molldrem, 1998, Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles, Br J Haematol, 102, 1314, 10.1046/j.1365-2141.1998.00920.x Killick, 2003, A pilot study of antithymocyte globulin (ATG) in the treatment of patients with ‘low-risk’ myelodysplasia, Br J Haematol, 120, 679, 10.1046/j.1365-2141.2003.04136.x Stadler, 2004, A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes, Leukemia, 18, 460, 10.1038/sj.leu.2403239 Aivado, 2002, Favourable response to antithymocyte or antilymphocyte globulin in low-risk myelodysplastic syndrome patients with a ‘non-clonal’ pattern of X-chromosome inactivation in bone marrow cells, Eur J Haematol, 68, 210, 10.1034/j.1600-0609.2002.01625.x Steensma, 2003, Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome, Blood, 101, 2156, 10.1182/blood-2002-09-2867 Broliden, 2006, Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes, Haematologica, 91, 667 Jonasova, 1998, Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow, Br J Haematol, 100, 304, 10.1046/j.1365-2141.1998.00551.x Shimamoto, 2003, Cyclosporin A therapy for patients with myelodysplastic syndrome: multicenter pilot studies in Japan, Leuk Res, 27, 783, 10.1016/S0145-2126(03)00008-0 D’Amato, 1994, Thalidomide is an inhibitor of angiogenesis, Proc Natl Acad Sci U S A, 91, 4082, 10.1073/pnas.91.9.4082 Raza, 2001, Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes, Blood, 98, 958, 10.1182/blood.V98.4.958 Musto, 2002, Thalidomide abolishes transfusion-dependence in selected patients with myelodysplastic syndromes, Haematologica, 87, 884 Strupp, 2002, Thalidomide for the treatment of patients with myelodysplastic syndromes, Leukemia, 16, 1, 10.1038/sj.leu.2402330 List, 2005, Efficacy of lenalidomide in myelodysplastic syndromes, N Engl J Med, 352, 549, 10.1056/NEJMoa041668 List, 2006, Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion, N Engl J Med, 355, 1456, 10.1056/NEJMoa061292 Raza A, Reeves JA, Feldman EJ, Dewald GW, Bennett JM, Deeg HJ et al. Phase II study of lenalidomide in transfusion-dependent, low- and intermediate-1-risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood Available online 24 September 2007. Gersuk, 1998, A role for tumour necrosis factor-alpha, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome, Br J Haematol, 103, 176, 10.1046/j.1365-2141.1998.00933.x Maciejewski, 2002, A pilot study of the recombinant soluble human tumour necrosis factor receptor (p75)-Fc fusion protein in patients with myelodysplastic syndrome, Br J Haematol, 117, 119, 10.1046/j.1365-2141.2002.03381.x Raza, 2004, Remicade as TNF suppressor in patients with myelodysplastic syndromes, Leuk Lymphoma, 45, 2099, 10.1080/10428190410001723322 Bellamy, 2001, Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes, Blood, 97, 1427, 10.1182/blood.V97.5.1427 Giles, 2003, SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes, Blood, 102, 795, 10.1182/blood-2002-10-3023 List, 2002, Randomized, Double-Blind Phase II Study of the Matrix Metalloprotease (MMP) Inhibitor, AG3340 (PrinomastatTM) in Patients with Myelodysplastic Syndrome (MDS), Blood, 100, 3119a Bonati, 2006, Arsenic trioxide in hematological malignancies: the new discovery of an ancient drug, Curr Pharm Biotechnol, 7, 397, 10.2174/138920106779116829 Schiller, 2006, Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes, J Clin Oncol, 24, 2456, 10.1200/JCO.2005.03.7903 Vey, 2006, Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study, J Clin Oncol, 24, 2465, 10.1200/JCO.2005.03.9503 Silverman, 2002, Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B, J Clin Oncol, 20, 2429, 10.1200/JCO.2002.04.117 Wijermans, 2000, Low-dose 5-aza-2’-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients, J Clin Oncol, 18, 956, 10.1200/JCO.2000.18.5.956 Kantarjian, 2006, Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study, Cancer, 106, 1794, 10.1002/cncr.21792 Graef, 2007, Successful treatment of relapsed AML after allogeneic stem cell transplantation with azacitidine, Leuk Res, 31, 257, 10.1016/j.leukres.2006.03.003 Kantarjian, 2007, Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia, Blood, 109, 52, 10.1182/blood-2006-05-021162 Khan, 2006, A pharmacodynamic study of 5-azacytidine in the P39 cell line, Exp Hematol, 34, 35, 10.1016/j.exphem.2005.09.007 Bhalla, 2004, Histone deacetylase inhibitors in myelodysplastic syndrome, Best Pract Res Clin Haematol, 17, 595, 10.1016/j.beha.2004.08.011 Kuendgen, 2005, Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia, Ann Hematol, 84, 61, 10.1007/s00277-005-0026-8 Germing, 2006, Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes, Haematologica/the Hematology Journal, 91, 1596 Kurzrock, 2003, Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting, Blood, 102, 4527, 10.1182/blood-2002-11-3359 Kurzrock, 2004, Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome, J Clin Oncol, 22, 1287, 10.1200/JCO.2004.08.082 Apperley, 2002, Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta, N Engl J Med, 347, 481, 10.1056/NEJMoa020150 Navas, 2006, Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors, Blood, 108, 4170, 10.1182/blood-2006-05-023093 Stofega, 2006, TelintraTM (TLK199) Enhances Granulocyte Colony-Stimulating Factor Production, Blood, 108, 1161a, 10.1182/blood.V108.11.1161.1161 Chan, 2002, Danazol for the treatment of thrombocytopenia in patients with myelodysplastic syndrome, Am J Hematol, 71, 166, 10.1002/ajh.10209 Yamada, 2003, Immunosuppressive therapy for myelodysplastic syndrome: efficacy of methylprednisolone pulse therapy with or without cyclosporin A, J Cancer Res Clin Oncol, 129, 485, 10.1007/s00432-003-0477-z Kaushansky, 1994, Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin, Nature, 369, 568, 10.1038/369568a0 Newland, 2006, An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura, Br J Haematol, 135, 547, 10.1111/j.1365-2141.2006.06339.x